NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Forecast & News

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IONS shares have increased by 0.5% and is now trading at $49.41. View which stocks have been mosted impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ionis Pharmaceuticals.

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Ionis Pharmaceuticals.

Ionis Pharmaceuticals Inc (NASDAQ:IONS) issued its quarterly earnings data on Wednesday, February, 26th. The company reported $1.28 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.91 by $0.37. The company had revenue of $494 million for the quarter, compared to analysts' expectations of $407.05 million. Ionis Pharmaceuticals had a net margin of 26.09% and a return on equity of 22.23%. The firm's revenue for the quarter was up 157.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.21 earnings per share. View Ionis Pharmaceuticals' earnings history.

Ionis Pharmaceuticals updated its FY 2020 Pre-Market earnings guidance on Wednesday, February, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $700 million, compared to the consensus revenue estimate of $814.68 million.

14 brokers have issued 1 year price targets for Ionis Pharmaceuticals' shares. Their forecasts range from $48.00 to $120.00. On average, they expect Ionis Pharmaceuticals' stock price to reach $74.46 in the next year. This suggests a possible upside of 50.7% from the stock's current price. View analysts' price targets for Ionis Pharmaceuticals.

News stories about IONS stock have trended somewhat positive on Saturday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutIonis Pharmaceuticals.

Ionis Pharmaceuticals saw a increase in short interest in the month of February. As of February 14th, there was short interest totaling 9,700,000 shares, an increase of 12.0% from the January 30th total of 8,660,000 shares. Based on an average daily trading volume, of 935,700 shares, the short-interest ratio is presently 10.4 days. Currently, 7.6% of the shares of the stock are short sold. View Ionis Pharmaceuticals' Current Options Chain.

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), Alibaba Group (BABA), BlackRock (BLK), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Gilead Sciences (GILD), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Allergan (AGN).

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (14.90%), Baillie Gifford & Co. (6.25%), BVF Inc. IL (1.55%), Renaissance Technologies LLC (1.45%), Geode Capital Management LLC (1.03%) and Norges Bank (0.86%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View institutional ownership trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Marshall Wace North America L.P., Pictet Asset Management Ltd., UBS Group AG, Jacobs Levy Equity Management Inc., Pinnacle Associates Ltd., Bank of America Corp DE, and Rafferty Asset Management LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, Elizabeth L Hougen, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke. View insider buying and selling activity for Ionis Pharmaceuticals.

IONS stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Norges Bank, Rockefeller Capital Management L.P., Baillie Gifford & Co., Scout Investments Inc., Renaissance Technologies LLC, Rothschild & Co. Asset Management US Inc., and Sumitomo Mitsui Trust Holdings Inc.. View insider buying and selling activity for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $49.41.

Ionis Pharmaceuticals has a market capitalization of $6.88 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe. View additional information about Ionis Pharmaceuticals.

The official website for Ionis Pharmaceuticals is http://www.ionispharma.com/.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.